RUNBEN BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.76 CNY | -0.75% |
|
-2.90% | +8.69% |
| Apr. 24 | Runben Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 7,356 | 7,995 | - | - |
| Enterprise Value (EV) 1 | 7,356 | 7,995 | 7,995 | 7,995 |
| P/E ratio | 28.4 x | 27.8 x | 22.2 x | 17.8 x |
| Yield | 0.94% | 0.98% | 1.21% | 1.37% |
| Capitalization / Revenue | 7.12 x | 5.93 x | 4.65 x | 3.7 x |
| EV / Revenue | 7.12 x | 5.93 x | 4.65 x | 3.7 x |
| EV / EBITDA | 25.8 x | 24 x | 18.9 x | 15.1 x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | 3.83 x | 3.71 x | 3.25 x | 2.84 x |
| Nbr of stocks (in thousands) | 404,593 | 404,593 | - | - |
| Reference price 2 | 18.18 | 19.76 | 19.76 | 19.76 |
| Announcement Date | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 1,033 | 1,348 | 1,720 | 2,164 |
| EBITDA 1 | - | 284.6 | 332.7 | 423.2 | 528.8 |
| EBIT 1 | - | 264.6 | 335.9 | 421.7 | 527.8 |
| Operating Margin | - | 25.62% | 24.93% | 24.53% | 24.39% |
| Earnings before Tax (EBT) 1 | - | 267.9 | 338.7 | 424.2 | 530.3 |
| Net income 1 | 160 | 226 | 286.7 | 359.8 | 448.7 |
| Net margin | - | 21.88% | 21.28% | 20.92% | 20.74% |
| EPS 2 | 0.4700 | 0.6400 | 0.7100 | 0.8900 | 1.110 |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | 0.1700 | 0.1933 | 0.2400 | 0.2700 |
| Announcement Date | 10/10/23 | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 22.6% | 13.5% | 15% | 16.2% |
| ROA (Net income/ Total Assets) | - | - | 12.7% | 14.1% | 14.8% |
| Assets 1 | - | - | 2,263 | 2,551 | 3,042 |
| Book Value Per Share 2 | - | 4.750 | 5.320 | 6.090 | 6.970 |
| Cash Flow per Share 2 | - | 0.6200 | 0.6000 | 0.8900 | 1.060 |
| Capex 1 | - | 13.6 | 75.2 | 72.6 | 102 |
| Capex / Sales | - | 1.32% | 5.58% | 4.22% | 4.72% |
| Announcement Date | 10/10/23 | 4/24/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
19.76
CNY
Average target price
23.77
CNY
Spread / Average Target
+20.28%
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- 603193 Stock
- Financials Runben Biotechnology Co., Ltd.
